title: ["Goldblatt phenomenon of the uterus" and latent kidney disease as the cause of pregnancy-induced hypertension--epidemiology and therapeutic consequences].
abstract: The aetiology of pregnancy-induced hypertension (PIH) is at present unknown. Epidemiological data lead us to assume, that two main mechanisms could be responsible for the development of PIH. They are not well understood in their complexity, but result in the same pattern of signs and symptoms: Oedema, proteinuria and hypertension. 1. "Goldblatt-Phenomenon" in the uterus, as a result of a disturbed maternal immune response to the cytotrophoblast, followed by the reduction of uterine blood flow and the liberation of vasoactive substances from the placenta. 2. Renal factors, especially in elderly women, result in a manifestation of nephrotic diseases during pregnancy. No screening methods are at the present time available to diagnose PIH in advance. It is therefore necessary, to look at typical clinical manifestations, i.e. the development of hypertension. It is also important to estimate the weight gain and the occurrence of oedema before rising blood pressure demonstrates a general vasoconstriction in the maternal vascular system. The basic therapeutical concept is to reduce the peripheral vascular resistance, to prevent maternal complications and to reduce the uterine vascular resistance to improve foetal oxygenation. In many cases an improvement of the oxygen supply to the foetus is not possible, since irreversible alterations of the uterine arterial vascular bed have already taken place. For the treatment of PIH, different drugs are available which act on different targets. In cases of special medical history, the early application of magnesium and acetyl salicylic acid (ASA) should be included in the therapeutical concept of prophylaxis.
authors.affiliation: Frauenklinik Justus-Liebig-Universität, Giessen.
authors.forename: W
authors.initials: W
authors.lastname: Künzel
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use; D011464:Epoprostenol / Q000502:physiology; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology*; D007231:Infant, Newborn; D011225:Pre-Eclampsia / Q000188:drug therapy / Q000503:physiopathology*; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy / Q000503:physiopathology*; D012084:Renin-Angiotensin System / Q000502:physiology; D013928:Thromboxane A2 / Q000502:physiology; D014599:Uterus / Q000098:blood supply*; D014655:Vascular Resistance / Q000502:physiology
chemical_list: D000959:Antihypertensive Agents; D013928:Thromboxane A2; D011464:Epoprostenol
vernacular_title: Das "Goldblatt-Phänomen am Uterus" und die latente Nierenerkrankung als Ursache der schwangerschaftsinduzierten Hypertonie--Epidemiologie und therapeutische Konsequenzen.